Literature DB >> 9545598

Kinetics of lactone hydrolysis in antitumor drugs of camptothecin series as studied by fluorescence spectroscopy.

I Chourpa1, J M Millot, G D Sockalingum, J F Riou, M Manfait.   

Abstract

Potent antitumor activity exhibited by 20-S-camptothecin (CPT) and numerous derivatives is known to be lost upon opening of the alpha-hydroxy-lactone ring of these drugs, hydrolyzable at neutral and basic pH. To quantify in 'real time' the lactone hydrolysis reaction in CPTs under physiological conditions, we have applied a non-perturbing approach by fluorescence spectroscopy. CPT and a set of its derivatives (21-lactam-S-CPT, 10,11-(methylenedioxy)-CPT, CPT-11, SN-38, topotecan, tricyclic ketone-CPT) with antitumor activity varying from negligible to 10 times that of CPT have been studied. Prior to the kinetic measurements, the effects of substitutions, pH, polarity of molecular environment, lactone ring opening (lactone-carboxylate transition) have been investigated in terms of the UV-visible absorption and fluorescence emission spectra of CPTs. Then the determined parameters of the fluorescence emission spectra corresponding to the respective lactone and carboxylate forms have been used to estimate the residual lactone percentage as a function of time. The reproducibility of the obtained data demonstrates that the spectroscopic approach provides a satisfactory precision for this kind of measurements. For CPT at pH 7.3, the lactone half-life was 29.4 +/- 1.7 min and the lactone percentage at equilibrium was 20.9 +/- 0.3%. Within a series of derivatives with substitutions at quinoline rings, the lactone half-life varied from 29 to 32 min and the equilibrium lactone content varied from 15% to 23%. For each compound, even slight increase of pH from 7.1 to 7.3 or from 7.3 to 7.6 logically leads to a remarkable decrease of both lactone half-life and equilibrium lactone percentage.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9545598     DOI: 10.1016/s0304-4165(97)00115-3

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  15 in total

1.  The mechanism of topoisomerase I poisoning by a camptothecin analog.

Authors:  Bart L Staker; Kathryn Hjerrild; Michael D Feese; Craig A Behnke; Alex B Burgin; Lance Stewart
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-08       Impact factor: 11.205

2.  Antitumor activity of peptide amphiphile nanofiber-encapsulated camptothecin.

Authors:  Stephen Soukasene; Daniel J Toft; Tyson J Moyer; Hsuming Lu; Hyung-Kun Lee; Stephany M Standley; Vincent L Cryns; Samuel I Stupp
Journal:  ACS Nano       Date:  2011-11-01       Impact factor: 15.881

3.  Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model.

Authors:  Ryuta Saito; Michal T Krauze; Charles O Noble; Daryl C Drummond; Dmitri B Kirpotin; Mitchel S Berger; John W Park; Krystof S Bankiewicz
Journal:  Neuro Oncol       Date:  2006-05-24       Impact factor: 12.300

4.  Intra and inter-molecular interactions dictate the aggregation state of irinotecan co-encapsulated with floxuridine inside liposomes.

Authors:  Awa Dicko; April A Frazier; Barry D Liboiron; Anne Hinderliter; Jeff F Ellena; Xiaowei Xie; Connie Cho; Tom Weber; Paul G Tardi; Donna Cabral-Lilly; David S Cafiso; Lawrence D Mayer
Journal:  Pharm Res       Date:  2008-03-05       Impact factor: 4.200

5.  PEAMOtecan, a novel chronotherapeutic polymeric drug for brain cancer.

Authors:  Jasmine Allen; Juan Wang; Olga Yu Zolotarskaya; Amrita Sule; Sajjad Mohammad; Shukaib Arslan; Kenneth J Wynne; Hu Yang; Kristoffer Valerie
Journal:  J Control Release       Date:  2020-02-03       Impact factor: 9.776

6.  Human multidrug resistance associated protein 4 confers resistance to camptothecins.

Authors:  Quan Tian; Jing Zhang; Theresa May Chin Tan; Eli Chan; Wei Duan; Sui Yung Chan; Urs Alex Boelsterli; Paul Chi-Lui Ho; Hongyuan Yang; Jin-Song Bian; Min Huang; Yi-Zhun Zhu; Weiping Xiong; Xiaotian Li; Shufeng Zhou
Journal:  Pharm Res       Date:  2005-11       Impact factor: 4.200

7.  Soluplus--solubilized citrated camptothecin--a potential drug delivery strategy in colon cancer.

Authors:  Naveen K Thakral; Alok R Ray; Daniel Bar-Shalom; André Huss Eriksson; Dipak K Majumdar
Journal:  AAPS PharmSciTech       Date:  2011-11-22       Impact factor: 3.246

8.  Tumor physiology and charge dynamics of anticancer drugs: implications for camptothecin-based drug development.

Authors:  D J Adams; L R Morgan
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

9.  Tracking the cell cycle origins for escape from topotecan action by breast cancer cells.

Authors:  G P Feeney; R J Errington; M Wiltshire; N Marquez; S C Chappell; P J Smith
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

10.  Supramolecular nanostructures formed by anticancer drug assembly.

Authors:  Andrew G Cheetham; Pengcheng Zhang; Yi-an Lin; Lye Lin Lock; Honggang Cui
Journal:  J Am Chem Soc       Date:  2013-02-13       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.